WO2009134725A3 - Monomethylamine progesteron antagonists such as cdb-4453 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc - Google Patents

Monomethylamine progesteron antagonists such as cdb-4453 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc Download PDF

Info

Publication number
WO2009134725A3
WO2009134725A3 PCT/US2009/041841 US2009041841W WO2009134725A3 WO 2009134725 A3 WO2009134725 A3 WO 2009134725A3 US 2009041841 W US2009041841 W US 2009041841W WO 2009134725 A3 WO2009134725 A3 WO 2009134725A3
Authority
WO
WIPO (PCT)
Prior art keywords
monomethylamine
dysmenorrhea
treatment
breast cancer
endometriosis
Prior art date
Application number
PCT/US2009/041841
Other languages
French (fr)
Other versions
WO2009134725A2 (en
Inventor
Joseph S. Podolski
Ronald D. Wiehle
Original Assignee
Repros Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repros Therapeutics Inc. filed Critical Repros Therapeutics Inc.
Publication of WO2009134725A2 publication Critical patent/WO2009134725A2/en
Publication of WO2009134725A3 publication Critical patent/WO2009134725A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Abstract

The subject matter of the instant invention is pertinent to the field of treatment of progesterone-dependent conditions. Compositions for practicing the methods, comprising one or more 19-norsteroid progesterone receptor modulators having a monomethylamine-substituted phenyl ring at the 11 β-position of carbon 11 and exhibiting low antiglucocorticoid activity, are also disclosed. Embodiments of the instant invention disclose methods for treating endometriosis, dysmenorrhea, breast cancer, uterine fibroids and endometrial hyperproliferation.
PCT/US2009/041841 2008-04-28 2009-04-27 Compositions and methods for treating progesterone-dependent conditions WO2009134725A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4845908P 2008-04-28 2008-04-28
US61/048,459 2008-04-28

Publications (2)

Publication Number Publication Date
WO2009134725A2 WO2009134725A2 (en) 2009-11-05
WO2009134725A3 true WO2009134725A3 (en) 2009-12-23

Family

ID=40756776

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/041841 WO2009134725A2 (en) 2008-04-28 2009-04-27 Compositions and methods for treating progesterone-dependent conditions

Country Status (3)

Country Link
CL (1) CL2009001012A1 (en)
TW (1) TW201002736A (en)
WO (1) WO2009134725A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0900171A2 (en) * 2009-03-20 2010-12-28 Richter Gedeon Nyrt Novel crystal form of 17-acetoxy-11›-[4-(dimethyl-amino)-phenyl]-21-metoxy-19-norpregna-4,9-dien-3,20-dione and process for it's preparation
HUP0900487A2 (en) * 2009-08-05 2011-03-28 Richter Gedeon Nyrt Novel crystal polymorphic form of 17-acetoxy-11 -[4-(dimethylamino)phenyl]-21-methoxy-4,9-diene-3,20-dione and process for it's preparation
US9603856B2 (en) * 2013-11-03 2017-03-28 Flamina Holding Ag Pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells
WO2016081383A1 (en) 2014-11-17 2016-05-26 Arno Therapeutics, Inc. Onapristone extended-release compositions and methods
US10308676B2 (en) 2015-09-25 2019-06-04 Context Biopharma Inc. Methods of making onapristone intermediates
US10548905B2 (en) 2015-12-15 2020-02-04 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
JP2019513706A (en) * 2016-03-21 2019-05-30 コンテキスト・バイオファーマ・インコーポレイテッド Onapristone metabolite composition and method
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041145A1 (en) * 1996-05-01 1997-11-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
WO2001074840A2 (en) * 2000-03-17 2001-10-11 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregna 21-substituted 19-norpregnadienedione as antiprogestational agents
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
WO2007103510A2 (en) * 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
WO2008067086A2 (en) * 2006-10-24 2008-06-05 Repros Therapeutics Inc. Compositions and methods for suppressing endometrial proliferation
WO2008129396A2 (en) * 2007-04-20 2008-10-30 Preglem S.A. Progesterone antagonist and selective progesterone modulator in the treatment of uterine bleeding

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041145A1 (en) * 1996-05-01 1997-11-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
WO2001074840A2 (en) * 2000-03-17 2001-10-11 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregna 21-substituted 19-norpregnadienedione as antiprogestational agents
WO2007103510A2 (en) * 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
WO2008067086A2 (en) * 2006-10-24 2008-06-05 Repros Therapeutics Inc. Compositions and methods for suppressing endometrial proliferation
WO2008129396A2 (en) * 2007-04-20 2008-10-30 Preglem S.A. Progesterone antagonist and selective progesterone modulator in the treatment of uterine bleeding

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ATTARDI BARBARA J ET AL: "CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: In vitro comparison to mifepristone and CDB-2914", MOLECULAR AND CELLULAR ENDOCRINOLOGY, ELSEVIER IRELAND LTD, IE, vol. 188, no. 1-2, 25 February 2002 (2002-02-25), pages 111 - 123, XP002496575, ISSN: 0303-7207 *
MEALY N E ET AL: "CDB-4124", DRUGS OF THE FUTURE 200411 ES, vol. 29, no. 11, November 2004 (2004-11-01), pages 1133, XP009118559, ISSN: 0377-8282 *

Also Published As

Publication number Publication date
TW201002736A (en) 2010-01-16
CL2009001012A1 (en) 2009-09-25
WO2009134725A2 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
WO2009134725A3 (en) Monomethylamine progesteron antagonists such as cdb-4453 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc
WO2009134718A8 (en) Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc
HK1169321A1 (en) Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer
CY1123239T1 (en) COMPOSITIONS AND METHODS FOR SUPPRESSING ENDOMETRIAL HYPERPLASIA
MX2009000714A (en) Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof.
MX2011013689A (en) Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators.
MY153078A (en) Compositions and methods for increasing muscle growth
MX2011012839A (en) Polycyclic antagonists of lysophosphatidic acid receptors.
MY161549A (en) Progesterone antagonists such as cdb-4124 in the treatment of breast cancer
EA200970646A1 (en) METHODS AND COMPOSITIONS FOR IMPROVING ANTI-PROGESTIN BIO-ACCESSIBILITY
MX2009010550A (en) Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof.
MX2010007391A (en) Trpa1 antagonists.
MX2009003981A (en) Calcium receptor modulating agents.
CU24106B1 (en) COMPOUNDS DERIVED FROM 6,7-DIHIDRO-5H-BENZO [7] ANNULARS
WO2011003100A3 (en) Compositions and methods for diagnosing and/or treating influenza infection
PL1989218T3 (en) 17-phosphorous steroid derivatives useful as progesterone receptor modulators
NZ602525A (en) Compositions and methods for non-toxic delivery of antiprogestins
WO2013086379A3 (en) Methods and compositions for treating antiprogestin-resistant cancers
EA200702604A1 (en) Derivatives of benzofuranone as a non-steroidal modulator of the progesterone receptor
MX2015004821A (en) Methods and compositions for treating progesterone-dependent conditions.
TN2015000454A1 (en) Progesterone receptor antagonist dosage form
MX2013006732A (en) Novel 19-nor-steroids and their use for treating progesterone-dependent conditions.
EA200702524A1 (en) NONSTEROID PROGESTERONE RECEPTOR MODULATORS
WO2008128791A3 (en) Progesterone-receptor antagonist for use in brca-mediated cancer alone or as combination with antiestrogen
UA98124C2 (en) Use of progesterone antagonist for the treatment of endometriosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09739527

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09739527

Country of ref document: EP

Kind code of ref document: A2